Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heterogeneous nuclear ribonucleoprotein A1 pseudogene 22 (HNRNPA1P22) is a non-protein-coding genomic sequence annotated as a pseudogene, related to the gene encoding hnRNP A1. Pseudogenes are genomically similar to protein-coding genes but generally do not produce functional proteins due to sequence changes. While some pseudogenes play regulatory roles in gene expression (e.g., acting as competitive endogenous RNAs), there is no reported evidence that HNRNPA1P22 is functionally active or targets any drugs. Its nomenclature should not be confused with the protein-coding hnRNP A1 gene, which is a well-established regulator of RNA metabolism and a therapeutic target in disease biology[1][7]. Key clarification: Despite similarity to HNRNPA1, HNRNPA1P22 is a pseudogene and not a classical therapeutic target; information regarding drugs, mechanism, biomarkers, or clinical application refers to the functional parent gene/protein, not the pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein A1 pseudogene 22 (HNRNPA1P22).